Fulcrum Therapeutics Inc. (FULC)
3.21
-0.03 (-0.93%)
At close: Mar 04, 2025, 11:53 AM
Fulcrum Therapeutics Ratios Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
| PE Ratio | -4.25 | -3.1 | -7.99 | -4.34 | -2.32 | -7.02 | -6.44 |
| PEG Ratio | 0.13 | -0.53 | 0.45 | 0.07 | -0.01 | 0.82 | n/a |
| PS Ratio | 147.54 | 51.65 | 32.64 | 33.65 | n/a | n/a | n/a |
| PB Ratio | 1.76 | 1.65 | 2.96 | 3.12 | 2.11 | 3.01 | 111.83 |
| P/FCF Ratio | -4.52 | -3.31 | -7.8 | -5.4 | -4.56 | -7.25 | -6.73 |
| P/OCF Ratio | -4.55 | -3.37 | -7.97 | -5.53 | -4.66 | -10.14 | -7.36 |
| OCF/S Ratio | -32.43 | -15.3 | -4.1 | -6.08 | n/a | n/a | n/a |
| Debt / Equity Ratio | 0.05 | 0.07 | n/a | 0.00 | 0.00 | 0.00 | 26.16 |
| Quick Ratio | 17.71 | 12.46 | 11.80 | 4.33 | 8.00 | 17.39 | 0.22 |
| Current Ratio | 17.71 | 12.41 | 11.77 | 4.23 | 8.24 | 17.52 | 0.48 |
| Asset Turnover | 0.01 | 0.03 | 0.08 | 0.07 | n/a | n/a | n/a |
| Interest Coverage | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Return on Equity (ROE) | -0.41 | -0.53 | -0.37 | -0.72 | -0.91 | -0.43 | -17.37 |
| Return on Assets (ROA) | -0.38 | -0.47 | -0.33 | -0.53 | -0.72 | -0.38 | -5.29 |
| Return on Capital (ROIC) | -0.45 | -0.54 | -0.38 | -0.7 | -0.86 | -0.41 | -14.79 |
| Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross Profit Margin | 100.00% | 61.94% | 86.88% | 73.04% | n/a | n/a | n/a |
| Net Profit Margin | -3.47K% | -1.67K% | -408.77% | -775.7% | n/a | n/a | n/a |
| Pretax Profit Margin | -3.47K% | -1.73K% | -421.89% | -802.66% | n/a | n/a | n/a |
| Operating Profit Margin | -3.95K% | -1.77K% | -422.97% | -811.64% | n/a | n/a | n/a |
| FCF Margin | -3.26K% | -1.56K% | -418.47% | -623.34% | n/a | n/a | n/a |
| EBITDA Margin | -3.87K% | -1.73K% | -409.85% | -784.68% | n/a | n/a | n/a |